LivaNova/$LIVN
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About LivaNova
UK-based LivaNova was born of a combination of Cyberonics in the US and Sorin in Italy. The medical-device firm is primarily focused on cardiopulmonary solutions (with heart-lung machines and oxygenation equipment) as well as neuromodulation devices for treatment-resistant epilepsy and depression. Following the merger, LivaNova divested its cardiac rhythm management, heart valve, and extracorporeal membrane oxygenation businesses. It derives roughly half of its revenue from the US market, another 21% from Europe, and the remainder from the rest of the world.
Ticker
$LIVN
Sector
Primary listing
Employees
3,300
Headquarters
Website
LivaNova Metrics
BasicAdvanced
$4bn
37.58
$1.94
0.82
-
Price and volume
Market cap
$4bn
Beta
0.82
52-week high
$74.32
52-week low
$41.02
Average daily volume
848k
Financial strength
Current ratio
1.33
Quick ratio
1.009
Long term debt to equity
27.396
Total debt to equity
28.353
Interest coverage (TTM)
5.06%
Profitability
EBITDA (TTM)
262.459
Gross margin (TTM)
67.83%
Net profit margin (TTM)
7.47%
Operating margin (TTM)
14.92%
Effective tax rate (TTM)
11.79%
Revenue per employee (TTM)
$430,000
Management effectiveness
Return on assets (TTM)
5.27%
Return on equity (TTM)
9.54%
Valuation
Price to earnings (TTM)
37.584
Price to revenue (TTM)
2.779
Price to book
3.3
Price to tangible book (TTM)
19.9
Price to free cash flow (TTM)
24.73
Free cash flow yield (TTM)
4.04%
Free cash flow per share (TTM)
2.949
Growth
Revenue change (TTM)
12.39%
Earnings per share change (TTM)
-147.46%
3-year revenue growth (CAGR)
11.11%
3-year earnings per share growth (CAGR)
8.27%
What the Analysts think about LivaNova
Analyst ratings (Buy, Hold, Sell) for LivaNova stock.
LivaNova Financial Performance
Revenues and expenses
LivaNova Earnings Performance
Company profitability
LivaNova News
AllArticlesVideos
LivaNova to Present at Goldman Sachs Global Healthcare Conference in June
Business Wire·19 hours ago
LivaNova Reports First-Quarter 2026 Results; Raises Full-Year 2026 Revenue and Adjusted Diluted EPS Guidance
Business Wire·2 weeks ago
Annals of Internal Medicine Publishes 12-Month Results from LivaNova's OSPREY Clinical Study for Obstructive Sleep Apnea
Business Wire·4 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for LivaNova stock?
LivaNova (LIVN) has a market cap of $4B as of May 20, 2026.
What is the P/E ratio for LivaNova stock?
The price to earnings (P/E) ratio for LivaNova (LIVN) stock is 37.58 as of May 20, 2026.
Does LivaNova stock pay dividends?
No, LivaNova (LIVN) stock does not pay dividends to its shareholders as of May 20, 2026.
When is the next LivaNova dividend payment date?
LivaNova (LIVN) stock does not pay dividends to its shareholders.
What is the beta indicator for LivaNova?
LivaNova (LIVN) has a beta rating of 0.82. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.